Levovir likely to remarketed this week

Published: 2009-05-12 06:57:00

Updated: 2009-05-12 06:57:00

The Food and Drug Administration will announce a plan to allow the re-sales of Levovir (clevudine) sooner or later, as the Central Pharmaceutical Affairs Review Committee made a final conclusion on May 7 that its risk benefit ratio is sufficient to do so.

Levovir is the 11th Korean new drug de...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK